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the incidence rate is 9.6 cases/10,000 in men 
and 11.1 cases/10,000 in women, with a total 
of around 61,000 cases [5]. In addition to its 
clinical impact, VTE also involves a heavy fi-
nancial burden for the NHS (National Health 
System) due not only to management of the 
acute episode, but also the management and 
prevention of long-term complications, such 
as recurrences of VTE, post-thrombotic syn-
drome and pulmonary hypertension [1]. The 
risk of recurrence is particularly high, with a 
recurrence rate of around 7% during the first 
6 months and increasing to 25% during the 5 
years following the acute episode [2,6]. Cor-
rect management of VTE must therefore pro-
vide not only appropriate, timely treatment of 
IntroductIon
Venous Thromboembolism (VTE), including 
pulmonary embolism (PE) and deep vein 
thrombosis (DVT) is a clinical condition as-
sociated with a high morbidity and mortality 
rate [1]. VTE is the third cause of cardiova-
scular death, with PE constituting a greater 
risk than DVT; in fact, 30-day mortality for 
patients with DVT is around 6% while for pa-
tients with PE it is around 12%, rising to 17% 
within 3 months [2].
The incidence of VTE in the general popu-
lation is around 70-120 cases/year/100,000 
inhabitants (one third of which are cases of 
PE with or without DVT and two third are ca-
ses of DVT) [2-4]. It is estimated that in Italy 
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BACKGROUND: Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a serious vascular condition associated to high economic and clinical burden. Apixaban, a Novel Oral 
Anticoagulant (NOAC) has shown non-inferiority efficacy versus the current standard of care (low molecular weight hepa-
rin [LMWH]/vitamin K antagonist [VKA]) in the acute treatment and prevention of VTE and a significant reduction in the 
risk of bleeding.
AIM: Evaluate the economic impact of the use of apixaban for treatment and prevention of DVT and PE from the perspec-
tive of the Italian National Health System (NHS).
METHODS: A budget impact model was adapted in order to compare clinical outcomes and economic consequences asso-
ciated to apixaban vs. LMWH/VKA and others NOACs over a three-year time horizon in the Italian setting. In the analysis 
two scenario were compared: status quo scenario without apixaban and an alternative scenario with apixaban. Only direct 
healthcare costs have been considered.
RESULTS: Assuming a population of patients receiving apixaban over the first 3 years equal to 20,957, the introduction 
of apixaban is associated to an incremental saving of € 821,748 in the first years, € 1,250,454 in the second year, and € 
1,866,466 in the third year. The total net saving over the 3-year period is € 3,938,668, which is a 2.47% decrease from the 
total budget for the status quo scenario without apixaban. This saving is mainly due to reduced VTE events and bleeds by 
apixaban. Indeed apixaban is associated with less VTE events (both fatal and non-fatal), less major bleeding and less Clini-
cal Relevant Non Major (CRNM) bleeding with a total of 52 fatal events avoided.
CONCLUSIONS: The listing of apixaban for the treatment of VTE (both DVT and PE) and the prevention of recurrent 
VTE provides both significant clinical advantages, in terms of deaths and events avoided, and economical advantages, 
consisting in a reduction in the total expenditure on the Italian NHS. 
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the acute episode, but also effective preven-
tion of recurrent events.
The standard treatment for VTE is an initial 
subcutaneous injection of low molecular 
weight heparin (LMWH) followed by oral 
therapy with vitamin K antagonists (VKA) 
[7]. The limitations of standard treatment 
relate to the parenteral administration of 
LMWH, which is potentially inconvenient in 
the case of treatment outside of hospital, and 
factors associated with VKA therapy, which 
could reduce patient compliance. These fac-
tors include interactions with drugs and food, 
the need for regular International Normalized 
Ratio (INR) monitoring, followed by the ne-
cessary dosage adjustments, and the risk of 
major bleeds [8].
In order to overcome the limitations associa-
ted with LMWH/VKA therapy, new antico-
agulant drugs have been developed, which 
are capable of simplifying even long-term 
patient management [9]. The novel oral an-
ticoagulants (NOACs) currently available 
(rivaroxaban, dabigatran, apixaban and edo-
xaban), indicated in the treatment and pre-
vention of recurrent VTE, have demonstrated 
similar efficacy and greater safety than the 
standard treatment, without the need for INR 
monitoring [10].
In May 2015, apixaban, previously indicated 
for the prevention of VTE in patients under-
going major orthopaedic surgery and in pre-
vention of stroke and systemic embolism in 
patients with non-valvular atrial fibrillation, 
obtained by the AIFA (Agenzia Italiana del 
Farmaco) approval and reimbursement also 
for the treatment and prevention of recurrent 
VTE [11]. Registration of the new indication 
was supported by the results of AMPLIFY 
(apixaban vs. enoxaparin/warfarin) [12] and 
AMPLIFY-EXT (apixaban vs. placebo) [13] 
multicentre, randomized, double blind, phase 
III studies.
The purpose of this analysis is to evaluate the 
impact on the Italian NHS budget of inclu-
ding apixaban in the current treatment mix 
(LMWH/VKA, rivaroxaban and dabigatran) 
for the treatment of acute episodes and the 
prevention of recurrent VTE in Italy.
MAterIAls And Methods
A budget impact model, previously develo-
ped but not yet published, was adapted to 
simulate the economic impact of apixaban 
vs. LMWH/VKA and others NOACs for tre-
atment and prevention of DVT and PE within 
an Italian cohort.
The budget impact analysis, performed using 
an analytical model developed in Microsoft 
Excel, was conducted from the perspective of 
the Italian NHS over a 3-year period accor-
ding to guidelines from ISPOR [14,15].
The financial impact from introducing apixa-
ban into the current prescribing pattern for 
the treatment and secondary prevention of 
VTE was estimated by analysing total costs 
in a cohort of patients with VTE eligible for 
treatment, and comparing a status quo sce-
nario in which apixaban is not yet available 
with an alternative scenario following the 
introduction of apixaban (Figure 1). In par-
ticular, costs relating to the acquisition and 
monitoring of drugs, the treatment of episo-
des of recurrent VTE and the management of 
clinical bleeding events (fatal bleeding, intra-
cranial bleeding – IC, major non-IC and cli-
nical relevant non-major – CRNM bleeding) 
were considered. Mortality associated with a 
recurrent VTE event or bleeding has also ta-
ken into account.
The estimated eligible population for tre-
atment over the 3 years of analysis was cal-
culated based on natural growth rates [16] 
using the population of Italy living there on 
1st January 2013 and applying a VTE inci-
dence rate of 0.1%, as reported by the study 
conducted by Cimminiello et al. [5], which 
retrospectively analysed the data of 372,000 
patients of 400 general practitioners between 
2001 and 2004. The percentage of patients 
that is undiagnosed, estimated at 30.6%, was 
excluded from the incident population. Fi-
nally, patients were subdivided based on the 
diagnosis of PE or DVT (33.3% and 66.7%, 
respectively according to epidemiological 
estimates) and patients thought not to be re-
ceiving treatment (0% of patients with PE 
and 2% of patients with DVT [Assumption] 
were excluded. The calculation of the target 
population is reported in Table I.
Treatment scenarios
Target patients were divided into the treatment 
regimens currently approved and prescribed 
in Italy for the treatment and prevention of 
VTE: NOACs (apixaban, dabigatran and ri-
varoxaban) and the standard treatment with 
LMWH/VKA (enoxaparin/warfarin). Edoxa-
ban was not included as it was not yet avai-
lable at the time of carrying out the analysis.
The percentage distribution of patients into 
the individual classes of available drugs de-
rives from a simulation of prescription sce-
narios in which the market share of NOACs 
is 50%, 55% and 60% in years 1, 2 and 3, 
respectively, with the remaining percentages 
(50%, 45% and 40%) belonging to LMWH/
VKA.
In the status quo scenario, in which apixa-
ban is not available, the market shares of the 
NOACs are divided between dabigatran and 
rivaroxaban, with percentages of 25% and 
75% of the total market shares of NOACs, 
respectively.
Figure 1. Scheme of the budget impact analysis
Year 1 Year 2 Year 3
Population (n.) 61,178,335 61,423,049 61,668,741
VTE incidence rate (%) 0.1
Non-diagnosed patients (%) 30.6
PE
 • Incidence (%) 33.3
 • Non-treated patients (%) 0
 • Treated patients (n.) 14,157 14,214 14,271
DVT
 • Incidence (%) 66.7
 • Non-treated patients (%) 2
 • Treated patients (n.) 27,748 27,859 27,971
Total treated patients (n.) 41,906 42,073 42,241
Table I. Calculation of the target population over the 3 years of analysis
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cranial bleeding – IC, major non-IC and cli-
nical relevant non-major – CRNM bleeding) 
were considered. Mortality associated with a 
recurrent VTE event or bleeding has also ta-
ken into account.
The estimated eligible population for tre-
atment over the 3 years of analysis was cal-
culated based on natural growth rates [16] 
using the population of Italy living there on 
1st January 2013 and applying a VTE inci-
dence rate of 0.1%, as reported by the study 
conducted by Cimminiello et al. [5], which 
retrospectively analysed the data of 372,000 
patients of 400 general practitioners between 
2001 and 2004. The percentage of patients 
that is undiagnosed, estimated at 30.6%, was 
excluded from the incident population. Fi-
nally, patients were subdivided based on the 
diagnosis of PE or DVT (33.3% and 66.7%, 
respectively according to epidemiological 
estimates) and patients thought not to be re-
ceiving treatment (0% of patients with PE 
and 2% of patients with DVT [Assumption] 
were excluded. The calculation of the target 
population is reported in Table I.
Treatment scenarios
Target patients were divided into the treatment 
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in Italy for the treatment and prevention of 
VTE: NOACs (apixaban, dabigatran and ri-
varoxaban) and the standard treatment with 
LMWH/VKA (enoxaparin/warfarin). Edoxa-
ban was not included as it was not yet avai-
lable at the time of carrying out the analysis.
The percentage distribution of patients into 
the individual classes of available drugs de-
rives from a simulation of prescription sce-
narios in which the market share of NOACs 
is 50%, 55% and 60% in years 1, 2 and 3, 
respectively, with the remaining percentages 
(50%, 45% and 40%) belonging to LMWH/
VKA.
In the status quo scenario, in which apixa-
ban is not available, the market shares of the 
NOACs are divided between dabigatran and 
rivaroxaban, with percentages of 25% and 
75% of the total market shares of NOACs, 
respectively.
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VTE incidence rate (%) 0.1
Non-diagnosed patients (%) 30.6
PE
 • Incidence (%) 33.3
 • Non-treated patients (%) 0
 • Treated patients (n.) 14,157 14,214 14,271
DVT
 • Incidence (%) 66.7
 • Non-treated patients (%) 2
 • Treated patients (n.) 27,748 27,859 27,971
Total treated patients (n.) 41,906 42,073 42,241
Table I. Calculation of the target population over the 3 years of analysis
In the scenario in which apixaban is availa-
ble, it is estimated that NOACs will represent 
a greater market share (60%, 65% and 70%) 
than LMWH-VKA (40%, 35% and 30%). 
In the case of apixaban, this is estimated to 
obtain 15%, 25% and 35% of prescriptions 
of NOACs over the three years of analysis. 
The remaining market shares of NOACs, i.e. 
51%, 48.75% and 45.5%, are divided betwe-
en dabigatran (25%) and rivaroxaban (75%).
Table II shows the estimated distribution of 
the different treatment regimens over the th-
ree years of analysis for the two scenarios 
considered.
Clinical events
The clinical events considered in the analysis 
include recurrent VTE (including episodes of 
non-fatal PE, non-fatal DVT and fatal VTE), 
major bleeding (including fatal bleeding, IC 
and non-IC bleeding) and CRNM bleeding.
The clinical event onset rates for apixaban 
comes from the AMPLIFY pivotal trial [12] 
with regard to the first 6 months following 
the start of treatment, and the AMPLIFY-
EXT pivotal trial [13] with regard to months 
6-18 post initiation of treatment.
These trials were conducted in order to eva-
luate the efficacy and safety of apixaban in 
treating PE and DVT and in preventing re-
current VTE after 6-12 months of treatment. 
In particular, the AMPLIFY study [12] invol-
ved 5,395 patients with an acute episode of 
VTE who were randomized to receive apixa-
ban 10 mg bid per os for 7 days, followed 
by 5 apixaban 5 mg bid per os for the next 6 
months or enoxaparin 1 mg/kg bid administe-
red subcutaneously for at least 5 days (until 
INR > 2) and warfarin per os for 6 months.
The study results demonstrated the non-
inferiority of apixaban compared with eno-
xaparin/warfarin in terms of incidence of 
recurrent fatal and non-fatal VTE (RR: 0.84; 
CI95%: 0.60-1.18) and its superiority com-
pared with enoxaparin/warfarin with regard 
to the primary safety endpoint (major bleeds 
RR: 0.31; CI95%: 0.17-0.55). Apixaban also 
significantly reduced the incidence of com-
posite endpoints comprising major/CRNM 
status quo scenario (without apixaban) alternative scenario (with apixaban)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
LMWH-VKA (%) 50.00 45.00 40.00 40.00 35.00 30.00
NOACs (%) 50.00 55.00 60.00 60.00 65.00 70.00
 • Apixaban - - - 9.00 16.25 24.50
 • Rivaroxaban 37.50 41.25 45.00 38.25 36.56 34.13
 • LMWH-dabigatran 12.50 13.75 15.00 12.75 12.19 11.37
Table II. Distribution of patient numbers in the scenario with and without apixaban
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bleeding (RR: 0.44; CI95%: 0.36-0.55) and 
VTE/mortality from VTE/major bleeding 
(RR: 0.62; CI95%: 0.47-0.83) [12]. The 
AMPLIFY-EXT study [13] was designed to 
determine the efficacy and safety of apixaban 
in preventing the recurrence of DVT and PE. 
2,482 patients were enrolled into the study, 
having completed 6 to 12 months of antico-
agulant therapy. They were randomized to 
treatment with apixaban 2.5 mg bid, 5 mg 
bid or placebo for 12 months. Both dosages 
of apixaban proved superior to the placebo 
in terms of preventing the recurrence of VTE 
and in terms of total mortality (2.5 mg = RR: 
0.33; CI95%: 0.22-0.48; 5 mg = RR: 0.36; 
CI95%: 0.25-0.53), while the incidence of 
major bleeding was similar in all three tre-
atment groups [13].
In the absence of any study carrying out a 
direct comparison, the relative risks for the 
comparators derive from two network meta-
analysis that were conducted to compare the 
efficacy and safety of anticoagulant for the 
initial, long-term and extended treatment of 
VTE [10,17]. The same risk of clinical event 
was taken into consideration for all patients 
who completed the treatment period, re-
gardless of the treatment they received.
Costs
In order to reflect the NHS’s perspective, the 
analysis only considered health costs directly 
relating to the acquisition and monitoring of 
drugs and to the inpatient or outpatient ma-
nagement of episodes of VTE and bleeding 
events. The cost for the first event of VTE 
was not taken into account, as it does not ge-
nerate any differential cost between scenario 
with and without apixaban.
Drugs
The drug acquisition costs are drawn from the 
Italian Official Gazette (OG General Series 
No. 246 of 22-10-2014). In keeping with cur-
rent legislation and what is stated by the OG, 
the direct distribution channel for apixaban, 
rivaroxaban, dabigatran and LMVH through 
hospitals (valued using the ex-factory price) 
and the territorial channel for warfarin (va-
lued using the retail price) were considered.
Treatment costs for both induction and pro-
phylactic phase were calculated based on the 
dosages shown in the SPCs of the drugs (Ta-
ble III).
The duration of treatment was assumed to be 
the same for all alternatives in both scenarios 
considered and it was estimated that 40% of 
patients remain under treatment for 3 months, 
30% for 6 months, 20% for 12 months and 
10% for 18 months. The cost of the LMWH 
injection was not taken into account as it was 
assumed to be self-administered by all pa-
tients.
INR monitoring is only counted in the case 
of warfarin, and as recommended by the 
guidelines of the Task Force on Pulmonary 
Embolism [18], 14 check-ups were taken 
into account during the first 3 months with 
1 check-up/month thereafter. The cost of the 
check-up was calculated based on the annual 
cost reported by Mennini et al. [19] and the 
frequency of monitoring reported by Pengo 
et al. [20] and was estimated at € 23.75.
Management of clinical events
The costs associated with managing recur-
rent VTE were estimated taking into account 
both inpatient and outpatient treatment. From 
a prospective study based on data from the 
MASTER registry, which gathered the data 
on 25 Italian centres about 2,119 patients suf-
fering an acute episode of VTE, we know that 
90.8% of patients were admitted to hospital 
after a VTE episode and only the 68.1% after 
a DVT episode [21].
In an inpatient setting, the cost per patient 
for the management of an episode of PE is 
€ 4,009, and it is € 2,315 for an episode of 
DVT.
The cost of managing an episode of non-fatal 
PE and DVT on an outpatient basis was esti-
mated at € 530.80 and € 318.89 respectively. 
Table IV shows the resources and sources 
used to estimate the cost and frequency of 
use. The cost of hospitalization following an 
episode of VTE comes from the price list for 
hospital services for acute patients [22], and 
in particular DRG 78 was used for PE and 
DRG 128 was used for DVT. The cost of tre-
ating an episode of fatal VTE was assumed 
to be the same as inpatient treatment for DVT 
(Table IV). 
Package
ex-factory 
price1 (€)
Unit cost 
(€)
Induction daily dose
Prophylactic 
daily dose
Apixaban 60 tablets 2.5 or 5 mg 66.97 1.12 10 mg bid (7 days) 10/5 mg/die2
Rivaroxaban 42 tablets 15 mg 92.57 2.20 15 mg bid (21 days) 20 mg/die
28 tablets 20 mg 61.71
LMWH3 10000 UI AXA/1 ml solution for 
injection 10 prefilled syringes 1 ml
66.34 6.63 1 mg/kg bid (7,64 days) -
Dabigatran 60 tablets 150 mg 66.97 1.12 - 150 mg bid
VKA (warfarin) 30 tablets 5 mg 2.174 0.07 5 mg/die (7,64 days) 5 mg/die
Table III. Daily cost and dosage of treatment with the various alternatives during the induction and prophylaxis phases
1 The drug acquisition costs were calculated based on hospital sales prices at the net of transitory legal price reductions (temporary reductions referred to 
AIFA Resolutions of 3/7/2006 and 27/09/2006) and mandatory discounts, estimates on the median of the tender prices
2 Apixaban 5 mg bid is administered for the first 6 months after the induction phase and the dose of 2.5 mg bid is administered thereafter
3 The cost of LMWH was estimated for a patient with an average weight of 84.6 kg treated with enoxaparin [12]
4 Retail price
The costs of managing bleeding events were 
calculated using the price list for hospital 
care for acute patients [22] (Table IV).
scenario analysis
In order to test the robustness of the results 
obtained and the parameters used in the base-
case, several scenario analyses were perfor-
med, in which the percentage of patients un-
der treatment for 3, 6, 12 and 18 months was 
changed. In particular, two different alternati-
ve scenarios were examined:
1. All patients treated for 6 months;
2. 30% of patients treated for 3 months, 
30% for 6 months, 30% for 12 months 
and 10% for 18 months;
Two different scenarios were also examined 
based on patient distribution:
3. One scenario in which the only NOAC 
available is apixaban, therefore in the 
scenario without apixaban all patients are 
reserved for LMWH-VKA. Following 
the introduction of apixaban there is an 
equal distribution of patients (base sce-
nario: LMWH-VKA = 100%; alternative 
scenario: LMWH-VKA = 50%/Apixaban 
= 50%); 
4. One scenario in which only NOACs are 
present, therefore in the scenario without 
apixaban, patients are divided equally 
between rivaroxaban and dabigatran. In 
the alternative scenario 100% of patients 
are equally divided between the three 
NOACs (status quo scenario: rivaroxa-
ban/dabigatran = 50%/50%; alternative 
scenario: apixaban/rivaroxaban/dabiga-
tran = 33.3%/33.3%/33.3%).
results
Table V shows the number of patients alloca-
ted to the different treatment strategies in the 
two scenarios analyzed in the base-case.
The results of the budget impact analysis 
show that for an estimated target population 
eligible for treatment and prevention of VTE 
of 41,905 patients for the first year, 42,073 
resource
Unit cost 
(€)
source
Frequency of 
use (n.) [23]
DVT Pe
Outpatient treatment
Doppler ultrasound 43.90 Cod. 88.77.2 [24] 1 1
CT angiography 184.80 Cod. 88.92.2 [24] 0 1
Echocardiogram 11.62 Cod. 89.52 [24] 0 1
D-Dimer test 4.99 Cod. 90.61.5 [24] 1 1
Chest X-ray 15.49 Cod. 87.44.1 [24] 0 1
Emergency admission 270.00 Italian Ministry 
of Health [25]
1 1
Inpatient treatment
Non-fatal PE 4,009.00 DRG 78 [22] - -
Non-fatal DVT 2,315.00 DRG 128 [22] - -
Fatal VTE 2,315.00 DRG 128 [22] - -
Bleeding events
IC 25,812.00 DRG 528 [22] - -
Major non-IC 3,317.00 DRG 174 [22] - -
CRNM 2,091.00 DRG 175 [22] - -
Fatal 3,891.00 DRG 14 [22] - -
Table IV. List of resources used to manage clinical events and the respective 
sources
Treated patients (n.)
status quo scenario (without apixaban) alternative scenario (with apixaban)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Apixaban 0 0 0 3,771 6,837 10,349
Rivaroxaban 15,714 17,355 19,009 16,029 15,382 14,417
LMWH-dabigatran 5,238 5,785 6,336 5,343 5,129 4,803
LMWH-VKA 20,953 18,933 16,896 16,762 14,726 12,672
Total 41,905 42,073 42,241 41,905 42,073 42,241
Table V. Distribution of patients between the different treatment strategies in both scenarios
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considered and it was estimated that 40% of 
patients remain under treatment for 3 months, 
30% for 6 months, 20% for 12 months and 
10% for 18 months. The cost of the LMWH 
injection was not taken into account as it was 
assumed to be self-administered by all pa-
tients.
INR monitoring is only counted in the case 
of warfarin, and as recommended by the 
guidelines of the Task Force on Pulmonary 
Embolism [18], 14 check-ups were taken 
into account during the first 3 months with 
1 check-up/month thereafter. The cost of the 
check-up was calculated based on the annual 
cost reported by Mennini et al. [19] and the 
frequency of monitoring reported by Pengo 
et al. [20] and was estimated at € 23.75.
Management of clinical events
The costs associated with managing recur-
rent VTE were estimated taking into account 
both inpatient and outpatient treatment. From 
a prospective study based on data from the 
MASTER registry, which gathered the data 
on 25 Italian centres about 2,119 patients suf-
fering an acute episode of VTE, we know that 
90.8% of patients were admitted to hospital 
after a VTE episode and only the 68.1% after 
a DVT episode [21].
In an inpatient setting, the cost per patient 
for the management of an episode of PE is 
€ 4,009, and it is € 2,315 for an episode of 
DVT.
The cost of managing an episode of non-fatal 
PE and DVT on an outpatient basis was esti-
mated at € 530.80 and € 318.89 respectively. 
Table IV shows the resources and sources 
used to estimate the cost and frequency of 
use. The cost of hospitalization following an 
episode of VTE comes from the price list for 
hospital services for acute patients [22], and 
in particular DRG 78 was used for PE and 
DRG 128 was used for DVT. The cost of tre-
ating an episode of fatal VTE was assumed 
to be the same as inpatient treatment for DVT 
(Table IV). 
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Prophylactic 
daily dose
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Rivaroxaban 42 tablets 15 mg 92.57 2.20 15 mg bid (21 days) 20 mg/die
28 tablets 20 mg 61.71
LMWH3 10000 UI AXA/1 ml solution for 
injection 10 prefilled syringes 1 ml
66.34 6.63 1 mg/kg bid (7,64 days) -
Dabigatran 60 tablets 150 mg 66.97 1.12 - 150 mg bid
VKA (warfarin) 30 tablets 5 mg 2.174 0.07 5 mg/die (7,64 days) 5 mg/die
Table III. Daily cost and dosage of treatment with the various alternatives during the induction and prophylaxis phases
1 The drug acquisition costs were calculated based on hospital sales prices at the net of transitory legal price reductions (temporary reductions referred to 
AIFA Resolutions of 3/7/2006 and 27/09/2006) and mandatory discounts, estimates on the median of the tender prices
2 Apixaban 5 mg bid is administered for the first 6 months after the induction phase and the dose of 2.5 mg bid is administered thereafter
3 The cost of LMWH was estimated for a patient with an average weight of 84.6 kg treated with enoxaparin [12]
4 Retail price
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calculated using the price list for hospital 
care for acute patients [22] (Table IV).
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eligible for treatment and prevention of VTE 
of 41,905 patients for the first year, 42,073 
resource
Unit cost 
(€)
source
Frequency of 
use (n.) [23]
DVT Pe
Outpatient treatment
Doppler ultrasound 43.90 Cod. 88.77.2 [24] 1 1
CT angiography 184.80 Cod. 88.92.2 [24] 0 1
Echocardiogram 11.62 Cod. 89.52 [24] 0 1
D-Dimer test 4.99 Cod. 90.61.5 [24] 1 1
Chest X-ray 15.49 Cod. 87.44.1 [24] 0 1
Emergency admission 270.00 Italian Ministry 
of Health [25]
1 1
Inpatient treatment
Non-fatal PE 4,009.00 DRG 78 [22] - -
Non-fatal DVT 2,315.00 DRG 128 [22] - -
Fatal VTE 2,315.00 DRG 128 [22] - -
Bleeding events
IC 25,812.00 DRG 528 [22] - -
Major non-IC 3,317.00 DRG 174 [22] - -
CRNM 2,091.00 DRG 175 [22] - -
Fatal 3,891.00 DRG 14 [22] - -
Table IV. List of resources used to manage clinical events and the respective 
sources
Treated patients (n.)
status quo scenario (without apixaban) alternative scenario (with apixaban)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Apixaban 0 0 0 3,771 6,837 10,349
Rivaroxaban 15,714 17,355 19,009 16,029 15,382 14,417
LMWH-dabigatran 5,238 5,785 6,336 5,343 5,129 4,803
LMWH-VKA 20,953 18,933 16,896 16,762 14,726 12,672
Total 41,905 42,073 42,241 41,905 42,073 42,241
Table V. Distribution of patients between the different treatment strategies in both scenarios
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for the second year and 42,241 patients for 
the third year, the introduction of apixaban 
into the current combination therapy for 
VTE, with annually increasing percentages 
of use, would mean a potential saving for the 
Italian NHS of € 821,748, € 1,250,454 and € 
1,866,466 in the course of the first, second 
and third year of treatment, respectively (Ta-
ble VI).
Figure 2 shows the cumulative results of the 
budget impact analysis for 3 year, resulting 
in a total saving for the Italian NHS of € 
3,938,668, due to the use of apixaban over a 
three-year period.
Table VII shows the annual cost per patient 
for the various treatment options considered 
in the analysis.
Table VIII shows the clinical events (episo-
des of recurrent fatal and non-fatal VTE) and 
major bleedings in both treatment scenarios 
 
Costs (€)
Year 1 Year 2 Year 3
status quo 
scenario1
alternative 
scenario2
status quo 
scenario1
alternative 
scenario2
status quo 
scenario1
alternative 
scenario2
Pharmaceutical 8,988,034 10,599,151 10,503,633 12,335,721 11,381,600 13,310,314
INR monitoring 8,746,631 6,997,305 8,198,914 6,383,498 7,320,371 5,497,694
Recurrent VTE events 7,946,260 7,924,638 16,077,039 16,044,535 24,501,867 24,453,720
Bleeding events 14,668,311 14,006,394 18,946,554 17,711,932 22,345,958 20,421,602
Total 40,349,236 39,527,488 53,726,140 52,475,686 65,549,796 63,683,330
Budget impact - 821,748 - 1,250,454 - 1,866,466
Table VI. Results of the budget impact analysis over three years
1 Without apixaban
2 With apixaban
Figure 2. Results of the cumulative budget impact analysis over three years
Costs (€/pts)
Pharmaceutical Inr monitoring recurrent VTe events Bleeding events Total
Year 1
Apixaban 418.96 0.00 183.96 176.43 3,137.25
Rivaroxaban 389.38 0.00 187.54 380.81 3,315.63
LMWH-dabigatran 418.64 0.00 195.64 251.50 3,223.70
LMWH-VKA 32.27 417.44 189.68 351.59 3,348.88
Year 2
Apixaban 439.16 0.00 291.22 220.50 3,308.75
Rivaroxaban 422.34 0.00 389.54 501.39 3,671.18
LMWH-dabigatran 456.32 0.00 396.92 340.71 3,551.84
LMWH-VKA 33.71 433.50 409.22 458.02 3,692.37
Year 3
Apixaban 443.16 0.00 385.30 257.98 3,444.32
Rivaroxaban 423.13 0.00 616.08 591.79 3,988.89
LMWH-dabigatran 457.23 0.00 623.71 430.46 3,869.29
LMWH-VKA 33.74 433.83 677.72 564.41 4,067.59
Table VII. Annual costs per patient for the various treatment options considered
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over the three years of analysis. The intro-
duction of apixaban make it possible to avoid 
36 new episodes of VTE (including 11 fatal 
episodes), 302 major bleeding events (inclu-
ding 41 fatal events) and 944 CRNM blee-
ding events, making a total of 1,282 fewer 
events over the course of three years.
scenario analysis
Tables IX and X and Figure 3 show the re-
sults of the scenario analysis.
dIscussIon
In recent years NOACs have become an im-
portant alternative to the standard therapy 
employed to treat acute episodes and prevent 
recurrent VTE. Although LMWH/VKA is 
still widely used in this setting, their good ef-
ficacy and safety profile and practicality have 
enabled the NOACs to gain large numbers 
of patients. Apixaban, a reversible, direct 
selective factor Xa inhibitor is an oral anti-
coagulant indicated in the treatment and pre-
vention of recurrent DVT and PE. Like the 
other drugs in its class it presents some bene-
fits with regard to standard treatment: no INR 
monitoring is necessary, the use of a fixed do-
sage, the lack of significant interactions with 
food and infrequent drug interactions. Mo-
reover, like rivaroxaban, but unlike dabiga-
tran, it does not require initial treatment with 
LMWH. The AMPLIFY study demonstrated 
the non-inferiority of apixaban to LMWH/
VKA with regard to the primary endpoint of 
efficacy, and its superiority with regard to the 
primary endpoint of safety; the AMPLIFY-
EXT study demonstrated that apixaban has 
a favourable profile in preventing the recur-
rence of VTE compared with placebo, with 
a similar major bleeding rate [12,13]. In the 
absence of direct comparative studies, some 
network meta-analyses have shown that 
apixaban is associated with a lower incidence 
Clinical events (n.)
status quo 
scenario1
alternative 
scenario2
avoided
VTE 20,747 20,711 36
 • Non-fatal PE 5,862 5,844 17
 • Non-fatal DVT 11,878 11,870 8
 • Fatal VTE 3,007 2,997 11
Major bleeding 4,189 3,887 302
 • IC 506 470 37
 • Non-IC 3,119 2,894 225
 • Fatal 564 523 41
CRNM 14,514 13,570 944
Table VIII. Clinical events over the three-year period in both treatment scenarios
1 Without apixaban
2 With apixaban
Costs (€)
status quo 
scenario1
alternative 
scenario2
Budget 
impact
Difference in budget 
impact: vs. base-case
Base-case
159,625,170 155,686,505 -3,938,665 -
scenario (a) – all patients treated for 6 months
143,562,978 139,858,168 -3,704,810 +233,855
scenario (b) – Treatment 3-6-12-18 months: 30%/30%/30%/10%
164,783,102 160,736,028 -4,047,074 -108,406
Table IX. Results of the scenario analysis relating to duration of treatment
1 Without apixaban
2 With apixaban
Costs (€)
status quo 
scenario1
alternative 
scenario2
Budget 
impact
Budget impact/
patient
scenario (c) – lMWh-VKa = 100% - lMWh-VKa/apixaban = 50%/50%
162,083,429 149,129,222 -12,954,207 -103
scenario (d) – nOaCs = 50%/50% - nOaCs = 33.3%/33.3%/33.3%
154,291,017 148,250,867 -6,040,150 -48
Table X. Results of the scenario analysis relating to patient distribution
1 Without apixaban
2 With apixaban
Figure 3. Results of the scenario analysis
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of major bleeding than the other NOACs in 
the acute treatment of VTE [10,26].
The current guidelines of the American Col-
lege of Chest Physicians (ACCP), published 
in 2016, suggest that the NOACs (dabigatran, 
rivaroxaban, apixaban and edoxaban) be gi-
ven preference over conventional therapy in 
the acute treatment of VTE in non-neoplastic 
patients [9]. A Technology Appraisal publi-
shed in June 2015 by the National Institute 
for Health and Clinical Excellence (NICE) 
recommends apixaban among the options for 
the treatment and secondary prevention of PE 
and DVT, also due to the favorable cost-effi-
cacy ratio that it has demonstrated compared 
with warfarin in the UK setting [27].
The financial benefit of apixaban has been 
confirmed by the results of this budget im-
pact analysis, in which the introduction of 
apixaban in the current mix of treatments for 
VTE is associated with a saving for the Italian 
NHS in terms of direct health costs relating 
to the treatment of recurrent VTE and blee-
ding episodes. In particular, if apixaban were 
to acquire 15%, 25% and 35% of the market 
shares of the NOACs, the saving for the NHS 
would amount to € 821,748, € 1,250,454 
and € 1,866,466 in the first, second and third 
year following its introduction, respectively, 
meaning a total saving of € 3,938,668 du-
ring the first three years of its use. The use 
of apixaban has also been associated with a 
reduction in the number of episodes of fatal 
and non-fatal recurrent VTE, major bleeding 
and CRNM bleeding, with a total of 52 fatal 
events avoided in three years.
As for all the economic evaluations, also in 
this analysis there are some limitations re-
sulting from the assumptions adopted in the 
development of the model, which may be 
affected by uncertainty. In the absence of 
RCTs that directly compare apixaban with 
other NOACs, relative risks derive from 
network meta-analysis [10,17], which is a 
type of analysis widely used in pharmacoe-
conomics evaluation [28] for overcoming the 
lack of head-to-head trials. Some credibility 
intervals of RRs obtained from the Bayesian 
fixed-effect network meta-analysis cross 1: in 
the classic interpretation of frequentist stati-
stics they would be considered as not signi-
ficant. However, the classical interpretation 
of statistical significance may not be applied 
directly to the Bayesian credibility interval, 
which indicates a plausible range of values 
[29]. Nevertheless, a sensitivity analysis in 
which these RR values are put equal to 1 
(apixaban and comparators have the same 
event risk) has been performed, showing a 
10% reduction of the savings at the year 3. 
However, the base-case analysis is to be con-
sidered conservative owing to the prudence 
of the assumptions made by the Authors: 
specifically, the inclusion of apixaban in the 
therapeutic arsenal for managing VTE deter-
mines an increase in treatment with NOACs 
compared with standard treatment (as assu-
med in the scenario with apixaban, in which 
the category of NOACs gains +10% of pa-
tients compared with the status quo scenario), 
which at the same time favors the entire cate-
gory, also allowing dabigatran and rivaroxa-
ban to gain patient numbers compared with 
the scenario without apixaban. This dynamic, 
known in microeconomics as the “knock-on 
benefit”, according to which the distribution 
of one product favors an increase in sales of 
the entire category, influences savings during 
the first year of analysis: specifically, patients 
treated with rivaroxaban and dabigatran are 
associated with higher VTE management 
costs than they would have been if all the pa-
tients gained in the category of NOACs had 
been under treatment with apixaban. 
Finally, the results of the scenario analyses 
confirmed the results of the budget impact 
analysis, suggesting the potentially greater 
benefit of apixaban when treatment is exten-
ded beyond 6 months. The scenario in which 
the percentages of patients under treatment 
for 3, 6, 12 and 18 months are equal to 30%, 
30%, 30% and 10%, respectively, actually 
further increased the saving achieved in the 
base-case by € 108,406. Finally, the scenario 
analyses performed by modifying patient di-
stribution also confirmed the benefit associa-
ted with apixaban, both in the case where pa-
tient numbers were shared only between the 
NOACs (BI = -6,040,150 €) and in the case 
where numbers were shared equally with 
LMWH/VKA (BI = -12,954,207 €).
conclusIons
The inclusion of apixaban in the current mix 
of available treatments for acute episodes of 
VTA and the prevention of recurrent VTE is 
associated with clinical benefits in terms of 
reducing recurrent fatal and non-fatal VTE 
events and bleeding episodes, and financial 
benefits in terms of impact on the budget of 
the Italian NHS.
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